(:CNST)

Jul 15, 2021 02:20 am ET
MorphoSys to Complete Transformational Acquisition of Constellation Pharmaceuticals, Bolstering Its Position in Hematology-Oncology
Company Announces Successful Completion of Tender Offer Moves Forward with Strategic Funding Partnership with Royalty Pharma
Jul 03, 2021 06:48 pm ET
INVESTIGATION ALERT: Halper Sadeh LLP Investigates IKNX, MPB, JAX, CNST; Shareholders are Encouraged to Contact the Firm
NEW YORK, July 3, 2021 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:
Jul 01, 2021 10:45 am ET
MorphoSys Announces Expiration of the Hart-Scott-Rodino Waiting Period for Acquisition of Constellation Pharmaceuticals
MUNICH, GERMANY and WILMINGTON, DE / ACCESSWIRE / July 1, 2021 / MorphoSys AG (FSE:MOR) (NASDAQ:MOR) ("MorphoSys") today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), for its tender offer for Constellation Pharmaceuticals, Inc., (NASDAQ:CNST) ("Constellation").
Jun 30, 2021 10:39 am ET
Lifshitz Law Firm, P.C. Announces Investigation of CNST, FFWM, SLCT, and GRA
Constellation Pharmaceuticals, Inc. (NasdaqGS: CNST) Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the sale of CNST to MOR for $34.00 in cash per share of CNST owned. If you are an...
Jun 29, 2021 09:00 am ET
INVESTIGATION ALERT: Halper Sadeh LLP Investigates RAVN, LDL, IKNX, CNST; Shareholders are Encouraged to Contact the Firm
Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Raven Industries, Inc. (NASDAQ: RAVN) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties...
Jun 23, 2021 12:01 pm ET
SHAREHOLDER ALERT: WeissLaw LLP Reminds KIN, FMBI, SLCT, and CNST Shareholders About Its Ongoing Investigations
If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: Joshua Rubin, Esq.WeissLaw LLP1500 Broadway, 16th...
Jun 22, 2021 05:32 pm ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates the Following Companies - CORE, MMAC, FMBI, CNST, SLCT
NEW YORK, June 22, 2021 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:
Jun 18, 2021 11:02 pm ET
INVESTOR ALERT: Monteverde & Associates Continues to Investigate the Following Merger
NEW YORK, June 18, 2021 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018-2020 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating:
Jun 17, 2021 11:55 am ET
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Reminds Investors of Investigation of CNST, USCR, SVBI, and QTS Buyouts
Rigrodsky Law, P.A. announces that it is investigating: Constellation Pharmaceuticals, Inc. (NASDAQ GS: CNST) regarding possible breaches of fiduciary duties and other violations of law related to Constellation’s agreement to be acquired by...
Jun 17, 2021 11:37 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates KIN, CNST, MDP, FMBI; Shareholders are Encouraged to Contact the Firm
Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Kindred Biosciences, Inc. (NASDAQ: KIN) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties...
Jun 16, 2021 12:20 pm ET
SHAREHOLDER ALERT: WeissLaw LLP Reminds FMBI, SLCT, CNST, and DISCA Shareholders About Its Ongoing Investigations
If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: Joshua Rubin, Esq.WeissLaw LLP1500 Broadway, 16th...
Jun 15, 2021 09:30 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates MMAC, ONB, CNST, SLCT; Shareholders are Encouraged to Contact the Firm
NEW YORK, June 15, 2021 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:
Jun 11, 2021 09:00 am ET
Constellation Pharmaceuticals Provides an Update from the Ongoing MANIFEST Study of Pelabresib
Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that three posters relating to the MANIFEST clinical trial...
Jun 09, 2021 01:04 pm ET
SHAREHOLDER ALERT: WeissLaw LLP Reminds COHR, FMBI, SLCT, and CNST Shareholders About Its Ongoing Investigations
If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: Joshua Rubin, Esq.WeissLaw LLP1500 Broadway, 16th...
Jun 08, 2021 03:09 pm ET
Moore Kuehn Encourages USCR, QTS, CNST and ESXB Investors to Contact Law Firm
NEW YORK, June 8, 2021 /PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders.  Moore Kuehn may seek increased consideration, additional disclosures, or other relief on behalf of the shareholders of these companies:
Jun 08, 2021 11:13 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates CLDR, FMBI, CNST, SLCT; Shareholders are Encouraged to Contact the Firm
Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Cloudera, Inc. (NYSE: CLDR) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to...
Jun 04, 2021 09:00 am ET
Constellation Pharmaceuticals Presents Phase 1 Data for CPI-0209 at ASCO Annual Meeting
Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today summarized in a poster presentation preliminary data from the...
Jun 03, 2021 02:27 pm ET
CONSTELLATION ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of CNST and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of Constellation Pharmaceuticals, Inc. (NASDAQ: CNST) breached their fiduciary duties or violated the...
Jun 02, 2021 10:50 am ET
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of Constellation Pharmaceuticals, Inc. Buyout
Rigrodsky Law, P.A. announces that it is investigating Constellation Pharmaceuticals, Inc. (“Constellation”) (NASDAQ GS: CNST) regarding possible breaches of fiduciary duties and other violations of law related to Constellation’s agreement to be...
Jun 02, 2021 10:14 am ET
Constellation Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Constellation Pharmaceuticals, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact t
Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Constellation Pharmaceuticals, Inc. (NASDAQ: CNST) to MorphoSys AG for $34.00 per share in cash is fair to Constellation shareholders.
Jun 02, 2021 07:40 am ET
Royalty Pharma Announces $2.025 Billion Strategic Funding Partnership With MorphoSys
Royalty Pharma plc (Nasdaq: RPRX) and MorphoSys AG (FSE: MOR; Nasdaq: MOR) today announced a $2.025 billion strategic funding partnership as part of MorphoSys’ $1.7 billion acquisition of Constellation Pharmaceuticals (Nasdaq: CNST). This...
Jun 02, 2021 07:25 am ET
MorphoSys to Acquire Constellation Pharmaceuticals
MorphoSys AG (FSE: MOR; NASDAQ: MOR) (“MorphoSys”), and Constellation Pharmaceuticals, Inc., (NASDAQ: CNST) (“Constellation”) today announced that they have entered into a definitive agreement whereby MorphoSys will acquire Constellation for $34.00 per share in cash, which represents a total equity value of $1.7 billion. The transaction has been unanimously approved by the management board (Vorstand) and the supervisory board (Aufsichtsrat) of MorphoSys, as well as the Board of Directors of Constellation and is expected to close in the third quarter of 2021.
May 31, 2021 09:00 am ET
Constellation Pharmaceuticals to Participate in Jefferies Virtual Healthcare Conference
Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that the Company will participate in an upcoming virtual...
May 10, 2021 07:00 am ET
Constellation Pharmaceuticals Announces First-Quarter 2021 Financial Results and Provides Business Update
Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced its first-quarter 2021 financial results. The Company also provided...
Apr 27, 2021 11:30 am ET
Constellation Pharmaceuticals to Host Conference Call to Discuss First Quarter 2021 Results
Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, will host a conference call at 8:00 AM EDT on May 10, 2021, to discuss its first quarter...
Feb 24, 2021 07:00 am ET
Constellation Pharmaceuticals Announces Fourth-Quarter and Full-Year 2020 Financial Results
Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced its fourth-quarter 2020 financial results and provided a business update....
Feb 19, 2021 04:00 pm ET
Constellation Pharmaceuticals to Participate in the 10th Annual SVB Leerink Global Healthcare Conference
Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that the Company will participate in an upcoming virtual...
Feb 18, 2021 10:00 am ET
Constellation Pharmaceuticals to Host Conference Call to Discuss Fourth Quarter 2020 Results
Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, will host a conference call at 8:00 AM EDT on February 24, 2021, to discuss its fourth...
Jan 07, 2021 09:30 am ET
Constellation Pharmaceuticals Appoints Brendan Delaney as Chief Commercial Officer
Constellation Pharmaceuticals, Inc. (Nasdaq: CNST) today announced the appointment of Brendan Delaney to the newly created position of Chief Commercial Officer, effective January 11, 2021. In this role, Mr. Delaney will be responsible for building...
Jan 06, 2021 10:00 am ET
Constellation Pharmaceuticals to Present at J.P. Morgan Healthcare Conference
Constellation Pharmaceuticals, Inc. (Nasdaq: CNST) today announced that Jigar Raythatha, CEO, will present a company overview at the J.P. Morgan Healthcare Conference at 10:50 AM EST on Thursday, January 14, 2021. A live audio webcast of the...
Dec 06, 2020 08:00 am ET
Constellation Pharmaceuticals Provides Update of MANIFEST Study for CPI-0610 at ASH Meeting
Constellation Pharmaceuticals, Inc. (Nasdaq: CNST) today announced that two oral presentations and three posters relating to the Phase 2 MANIFEST and the Phase 3 MANIFEST-2 clinical trials of CPI-0610 in myelofibrosis (MF) were presented at the...
Nov 23, 2020 01:00 pm ET
Constellation Pharmaceuticals to Host Analyst / Investor Event to Discuss Update of MANIFEST Clinical Trial for CPI-0610 Presented at ASH Meeting
Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, will host a virtual analyst/investor event and conference call on December...
Oct 29, 2020 07:00 am ET
Constellation Pharmaceuticals Announces Third-Quarter 2020 Financial Results
Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced its third-quarter 2020 financial results. The Company also provided...
Oct 19, 2020 02:00 pm ET
Constellation Pharmaceuticals to Host Conference Call to Discuss Third Quarter 2020 Results
Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, will host a conference call at 8:00 AM EDT on October 29, 2020, to discuss its third...
Sep 09, 2020 03:00 pm ET
Constellation Pharmaceuticals to Participate in Upcoming Virtual Investor Conferences
Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that the Company will participate in upcoming virtual...
Aug 05, 2020 07:00 am ET
Constellation Pharmaceuticals Announces Second-Quarter 2020 Financial Results, Provides Regulatory Update
Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced its second-quarter 2020 financial results. Constellation...
Jul 31, 2020 12:00 pm ET
Constellation Pharmaceuticals to Host Conference Call to Discuss Second Quarter 2020 Results
Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, will host a conference call at 8:00 AM EDT on August 5, 2020, to discuss its second...
Jun 16, 2020 08:27 pm ET
Constellation Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Constellation Pharmaceuticals, Inc., (Nasdaq: CNST) a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that it has priced an underwritten public offering of...
Jun 15, 2020 04:01 pm ET
Constellation Pharmaceuticals Announces Proposed Public Offering of Common Stock
Constellation Pharmaceuticals, Inc., (Nasdaq: CNST) a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that it has commenced an underwritten public offering of...
Jun 12, 2020 02:30 am ET
Constellation Pharmaceuticals Provides Updates of MANIFEST Study for CPI-0610 and EZH2 Franchise
Constellation Pharmaceuticals, Inc. (Nasdaq: CNST) today announced that three posters relating to the MANIFEST clinical trial of CPI-0610 in myelofibrosis (MF) were published online in association with the European Hematology Association (EHA)...
Jun 10, 2020 11:30 am ET
Constellation Pharmaceuticals to Participate in Investor Conference
Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that the Company will participate in an upcoming virtual...
Jun 08, 2020 08:00 am ET
Constellation Pharmaceuticals Announces Appointment of Dr. Jeffrey Humphrey as Chief Medical Officer
Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that Jeffrey Humphrey, M.D., will join Constellation Pharmaceuticals as...
May 29, 2020 09:00 am ET
Constellation Pharmaceuticals to Participate in Investor Conference
Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that the Company will participate in an upcoming virtual...
May 28, 2020 12:00 pm ET
Constellation Pharmaceuticals to Host Analyst / Investor Event to Discuss Update of MANIFEST Clinical Trial for CPI-0610
Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, will host a virtual analyst/investor event and conference call on June 12...
May 14, 2020 08:00 am ET
Constellation Pharmaceuticals Provides Update of Preliminary Data for CPI-0610 in Three EHA Abstracts
Constellation Pharmaceuticals, Inc. (Nasdaq: CNST) today announced that three abstracts relating to the MANIFEST clinical trial of CPI-0610 in myelofibrosis were published online in association with the European Hematology Association (EHA) annual...
May 06, 2020 07:00 am ET
Constellation Pharmaceuticals Announces First-Quarter 2020 Financial Results
Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced its first-quarter 2020 financial results. “In the face of the serious...
May 05, 2020 02:06 pm ET
Constellation Pharmaceuticals to Participate in Two Investor Conferences
Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that the Company will participate in two upcoming virtual...
Apr 28, 2020 09:00 am ET
Constellation Pharmaceuticals to Host Conference Call to Discuss First Quarter 2020 Results
Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, will host a conference call at 8:00 AM EDT on May 6, 2020, to discuss its first quarter...
Apr 06, 2020 07:00 am ET
Constellation Pharmaceuticals Announces Appointment of Dr. Richard Levy to Board of Directors
Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that Richard Levy, M.D., has been appointed to its Board...
Mar 10, 2020 04:12 pm ET
Constellation Pharmaceuticals Announces Fourth-Quarter and Full-Year 2019 Financial Results
Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced its fourth-quarter and full-year 2019 financial results. “The fourth...
Mar 06, 2020 01:00 pm ET
Constellation Pharmaceuticals to Host Conference Call to Discuss Fourth Quarter 2019 Results
Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, will host a conference call at 5:00 PM EDT on March 10, 2020, to discuss its fourth...
Feb 26, 2020 09:00 am ET
Constellation Pharmaceuticals to Present at Investor Conferences
Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that Jigar Raythatha, CEO, will present a company overview...
Jan 06, 2020 12:34 pm ET
Constellation Pharmaceuticals to Present at J.P. Morgan Healthcare Conference
Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that Jigar Raythatha, CEO, will present a company overview...
Dec 13, 2019 04:05 pm ET
Constellation Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
Constellation Pharmaceuticals, Inc., (Nasdaq: CNST) a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced closing of its previously announced underwritten public...
Dec 10, 2019 09:05 pm ET
Constellation Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Constellation Pharmaceuticals, Inc., (Nasdaq: CNST) a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that it has priced an underwritten public offering of...
Dec 09, 2019 04:18 pm ET
Constellation Pharmaceuticals Announces Proposed Public Offering of Common Stock
Constellation Pharmaceuticals, Inc., (Nasdaq: CNST) a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that it has commenced an underwritten public offering of...
Dec 09, 2019 10:00 am ET
Constellation Pharmaceuticals Provides Updated Preliminary Data from MANIFEST Clinical Trial with CPI-0610 in Oral and Poster Presentations at ASH
Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today provided an update of preliminary data from the MANIFEST clinical trial in oral and...
Dec 02, 2019 11:00 am ET
Constellation Pharmaceuticals to Host Analyst/Investor Meeting at ASH to Discuss Updated Preliminary Data from the MANIFEST Clinical Trial with CPI-0610
Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, will host an analyst/investor event and webcast on December 9 at 12:30 PM...
Nov 13, 2019 09:00 am ET
Constellation Pharmaceuticals to Participate in Upcoming Investor Conferences
Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that Jigar Raythatha, CEO, will present at three upcoming...
Nov 06, 2019 09:00 am ET
Constellation Pharmaceuticals Announces Third-Quarter and Nine-Month 2019 Financial Results
Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced its third-quarter and nine-month 2019 financial results. “Our clinical...
Oct 10, 2019 07:00 am ET
Constellation Pharmaceuticals Announces MANIFEST Data Updates Will Be Provided in Oral and Poster Sessions on December 9 at ASH
Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that the Company will present updates of clinical data...
Oct 01, 2019 07:00 am ET
Constellation Pharmaceuticals Announces $65 Million Private Placement with New and Existing Investors
Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that it has entered into a securities purchase agreement...
Sep 26, 2019 12:00 pm ET
Constellation Pharmaceuticals to Present at Cantor Global Healthcare Conference
Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that Jigar Raythatha, CEO, will present at the Cantor...
Sep 24, 2019 07:00 am ET
Constellation Pharmaceuticals Advances CPI-0209 into Clinical Trials, Expanding its EZH2 Franchise
Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that the Company has dosed the first patient in a Phase...
Aug 21, 2019 09:00 am ET
Constellation Pharmaceuticals to Participate in Two Investor Conferences
Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that the Company will participate in two investor...
Aug 07, 2019 04:05 pm ET
Constellation Pharmaceuticals Announces Second-Quarter and Six-Month 2019 Financial Results
Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced its second-quarter and six-month 2019 financial results. “2019 is a year...
Jun 13, 2019 02:57 pm ET
Constellation Pharmaceuticals to Present at BMO Prescriptions for Success Healthcare Conference
Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that Jigar Raythatha, CEO, will present at the BMO...
Jun 12, 2019 09:00 am ET
Constellation Pharmaceuticals Presentation Highlights Enhanced EZH2 Target Engagement, Leading to Second-Generation EZH2 Inhibitor CPI-0209
Constellation Pharmaceuticals, Inc. (Nasdaq: CNST) today announced that Dr. Jacob Stuckey, Senior Scientist at Constellation Pharmaceuticals, gave an oral presentation titled Methods for Kinetic Assessment of High Affinity EZH2 Inhibitors:...
Jun 03, 2019 09:00 am ET
Interim Data for CPI-0610 in MANIFEST Clinical Trial Showed Signals of Clinical Activity in Myelofibrosis Patients
Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced the presentation of updated interim data from MANIFEST,...
May 31, 2019 11:00 am ET
Constellation Pharmaceuticals to Present at Jefferies Healthcare Conference
Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that Jigar Raythatha, CEO, will present at the Jefferies...
May 23, 2019 10:28 am ET
Constellation Pharmaceuticals to Host Analyst/Investor Meeting at ASCO to Discuss Interim Update of Data of CPI-0610 in MANIFEST Clinical Trial
Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, will host an analyst/investor event and webcast on June 4 at 7:00 AM CDT...
May 20, 2019 07:00 am ET
Constellation Pharmaceuticals Presents Poster on Studies of CPI-0209 in Bladder Cancer at AACR Meeting
Constellation Pharmaceuticals, Inc. (Nasdaq: CNST) today announced that Dr. Patricia Keller, Senior Scientist at Constellation Pharmaceuticals, presented a poster titled Targeting epigenetic dysregulation in bladder cancer through inhibition of...
May 16, 2019 09:00 am ET
Constellation Pharmaceuticals Provides Interim Update of Data for CPI-0610 in ASCO and EHA Abstracts
Constellation Pharmaceuticals, Inc. (Nasdaq: CNST) today announced that two abstracts relating to the MANIFEST clinical trial of CPI-0610 for myelofibrosis – one in association with the American Society for Clinical Oncology (ASCO) annual meeting...
May 08, 2019 04:15 pm ET
Constellation Pharmaceuticals Announces First-Quarter 2019 Financial Results
Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, announced its first-quarter 2019 financial results today. “2019 is a year...
Apr 19, 2019 08:00 am ET
Constellation Pharmaceuticals to Present at the Solebury Trout Class of 2018 Biotech IPOs Investor Day
Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that Jigar Raythatha, CEO, will be participating and...
Apr 09, 2019 08:55 am ET
Report: Exploring Fundamental Drivers Behind The Cooper Companies, Encompass Health, SilverCrest Metals, Constellation Pharmaceuticals, Leaf Group, and TESSCO Technologies — New Horizons, Emerging Tre
In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of The Cooper Companies, Inc. (NYSE:COO), Encompass Health Corporation (NYSE:EHC),...
Apr 01, 2019 01:00 pm ET
Constellation Pharmaceuticals Presents Results from Phase 1b Portion of ProSTAR Clinical Trial of CPI-1205 at AACR Meeting
Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today presented results from the Phase 1b portion of the ProSTAR clinical...
Mar 14, 2019 05:24 pm ET
Constellation Pharmaceuticals Announces Fourth-Quarter and Full-Year 2018 Financial Results
Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced its fourth-quarter and full-year 2018 financial results....
Mar 06, 2019 02:35 pm ET
Constellation Pharmaceuticals to Present at Upcoming Investor Conference
Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that Jigar Raythatha, CEO, will present at the Oppenheimer...
Mar 04, 2019 07:00 am ET
Constellation Pharmaceuticals Appoints Jessica Christo as Chief Product Development Officer
Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that Jessica Christo has been appointed Chief Product...
Feb 22, 2019 01:24 pm ET
Constellation Pharmaceuticals to Present at Upcoming Investor Conferences
Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that Jigar Raythatha, CEO, will present at the SVB Leerink...
Feb 20, 2019 07:00 am ET
Constellation Pharmaceuticals Announces Appointment to Board of Directors
Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that Scott Braunstein, M.D., has been appointed to its...
Jan 03, 2019 07:00 am ET
Constellation Pharmaceuticals Provides Update on MANIFEST Clinical Trial of CPI-0610 in Myelofibrosis, Reviews 2018 Accomplishments, and Announces 2019 Data Disclosure Plans for Lead Programs
Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today provided an update on progress in the MANIFEST Phase 2 clinical...
Dec 20, 2018 01:34 pm ET
Constellation Pharmaceuticals to Present at J.P. Morgan Healthcare Conference
Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that Jigar Raythatha, CEO, will present at the J.P....
Dec 10, 2018 04:49 pm ET
Constellation Pharmaceuticals Initiates Phase 2 Portion of ProSTAR Clinical Trial in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced an update of the ProSTAR study, its ongoing Phase 1b/2...
Nov 29, 2018 02:00 pm ET
Constellation Pharmaceuticals to Present at BMO Healthcare Conference
Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that Jigar Raythatha, CEO, will present at the BMO 2018...
Nov 29, 2018 09:22 am ET
Constellation Pharmaceuticals Appoints Patrick Trojer, Ph.D., as Chief Scientific Officer
Constellation Pharmaceuticals, Inc. (the “Company”) (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that Patrick Trojer has been appointed...
Nov 21, 2018 07:20 am ET
Factors of Influence in 2018, Key Indicators and Opportunity within Sphere 3D, Solar Senior Capital, The Intergroup, Constellation Pharmaceuticals, Sonoma Pharmaceuticals, and OFS Capital — New Resear
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Sphere 3D Corp. (NASDAQ:ANY), Solar Senior Capital Ltd. (NASDAQ:SUNS), The...
Nov 15, 2018 07:00 am ET
Constellation Pharmaceuticals Highlights EZH2 Inhibition Program in Prostate Cancer at Biomedical Conference
Constellation Pharmaceuticals, Inc., (Nasdaq: CNST) a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, will make a presentation on its EZH2 inhibition program in prostate cancer...
Nov 08, 2018 04:30 pm ET
Constellation Pharmaceuticals Announces Third-Quarter and Nine-Month 2018 Financial Results
Constellation Pharmaceuticals, Inc., (Nasdaq: CNST) a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced its third-quarter and nine-month 2018 financial results....
Nov 02, 2018 01:08 pm ET
Constellation Pharmaceuticals to Present at Upcoming Investor Conferences
Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that the Company will present at two investor conferences...
Nov 01, 2018 07:00 am ET
Constellation Pharmaceuticals Receives FDA Fast Track Designation for CPI-0610 in Treatment of Myelofibrosis
Constellation Pharmaceuticals, Inc. (NASDAQ:CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that it has received Fast Track designation from the United...
Oct 10, 2018 04:30 pm ET
Constellation Pharmaceuticals Enhances and Expands Phase 2 MANIFEST Study of CPI-0610 in Myelofibrosis
Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced several planned updates to the Phase 2 portion of its...
Sep 12, 2018 09:00 am ET
Constellation Pharmaceuticals Congratulates Dr. David Allis and Dr. Michael Grunstein, Winners of the 2018 Lasker Award
Constellation Pharmaceuticals, Inc. (Nasdaq: CNST) today congratulated Dr. C. David Allis and Dr. Michael Grunstein, the co-recipients of the 2018 Albert Lasker Basic Medical Research Award.  These two eminent scientists were honored for their...
Sep 04, 2018 06:30 am ET
Constellation Pharmaceuticals Announces Appointments to Board of Directors
Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that Dr. Elizabeth G. Tréhu and Steven L. Hoerter have...
Aug 14, 2018 04:15 pm ET
Constellation Pharmaceuticals Announces Second-Quarter and Six-Month 2018 Financial Results
Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced its second-quarter and six-month 2018 financial results....

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.